


Article

Dynamic Resistance Exercise Alters Blood ApoA-I Levels, Inflammatory Markers, and Metabolic Syndrome Markers in Elderly Women

Nayoung Ahn and Kijin Kim * 

Department of Physical Education, Keimyung University, Daegu 42601, Korea

* Correspondence: kjk744@kmu.ac.kr

Abstract: Combined endurance and dynamic-resistance exercise has important anti-inflammatory effects, altering vascular endothelial function, and helping to prevent and treat aging-related metabolic syndrome (MS). We studied changes in 40 elderly women aged ≥ 65 years (control group (no MS), $n = 20$, mean age: 68.23 ± 2.56 years; MS group, $n = 19$, mean age: 71.42 ± 5.87 years; one left). The exercise program comprised dynamic-resistance training using elastic bands, three times weekly, for six months. We analyzed body composition, blood pressure, physical fitness, and MS-related blood variables including ApoA-I, antioxidant factors, and inflammatory markers. After the program, the MS group showed significant reductions in waist-hip ratio, waist circumference, diastolic blood pressure, blood insulin, and HOMA-IR, and a significant increase in HSP70 ($p < 0.05$). Both groups showed significant increases in ApoA-I levels, ApoA-I/HDL-C ratio, SOD2, IL-4, and IL-5 levels ($p < 0.05$). Active-resistance training-induced changes in ApoA-I were significantly positively correlated with changes in HDL-C and HSP70, and significantly negatively correlated with changes in triglycerides, C-reactive protein, and TNF- α ($p < 0.05$). Active-resistance training qualitatively altered HDL, mostly by altering ApoA-I levels, relieving vascular inflammation, and improving antioxidant function. This provides evidence that dynamic-resistance exercise can improve physical fitness and MS risk factors in elderly women.

Keywords: dynamic-resistance exercise; elderly women; metabolic syndrome; ApoA-I; inflammation; physical fitness; dysfunctional HDL-C; cardiovascular risk; vascular endothelial function; antioxidant function



Citation: Ahn, N.; Kim, K. Dynamic Resistance Exercise Alters Blood ApoA-I Levels, Inflammatory Markers, and Metabolic Syndrome Markers in Elderly Women. *Healthcare* **2022**, *10*, 1982. <https://doi.org/10.3390/healthcare10101982>

Academic Editor: Chrysi Koliaki

Received: 10 August 2022

Accepted: 6 October 2022

Published: 9 October 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Among cardiovascular risk factors, high-density lipoprotein cholesterol (HDL-C) is considered a key positive health indicator. Reduced HDL-C increases the risk of coronary artery disease (CAD) [1,2], while increased HDL-C reduces the risk of CAD and myocardial infarction. While the inverse relationship between HDL-C and cardiovascular disease (CVD) has long been known [3], the qualitative characteristics of HDL-C are more relevant in preventing CVD than its quantitative characteristics [4,5]. These qualitative characteristics, therefore, provide important prognostic factors of CVD [6]. Further, the structure of HDL-C can affect its cardioprotective function [7].

HDL-C has anti-atherogenic [8], anti-inflammatory, anti-apoptotic, and anti-thrombotic effects [9–12]. In a normal environment, HDL can prevent oxidation of low-density lipoprotein (LDL), whereas, in pathological states such as oxidative stress, inflammation, or diabetes, it exhibits dysfunctional HDL-C structure, with reduced anti-arteriosclerosis and anti-inflammatory functions [6]. Dysfunctional HDL-C is associated with reduced apolipoprotein A-1 (ApoA-I) and increased serum amyloid A (SAA). Changes in levels of dysfunctional HDL-C can be quantitatively determined by analyzing ApoA-I and SAA levels, by separating the small, high-density subtype HDL3 [13,14]. HDL undergoes structural and compositional changes that alter its anti-arteriosclerosis and anti-inflammatory

effects. While it is important to examine how HDL levels, substructure, and composition alter metabolic syndrome (MS) risk, few prior studies have addressed this.

Regular exercise is widely known to improve CVD, raising blood HDL-C and reducing blood triglyceride levels and blood pressure [15–17]. Aerobic exercise programs can alter ApoA-I, reducing inflammation and therefore the risk of CAD [18–22]. This provides further evidence that aerobic exercise promotes antioxidative, anti-inflammatory, and HDL-mediated positive effects on vascular endothelial function in MS patients.

Health-improvement exercise programs by the American College of Sports Medicine (ACSM) [23], the European College of Sport Science (ECSS) [24], and the American Heart Association (AHA) [25] emphasize the importance of at least five weekly sessions of endurance exercise, or at least three sessions of high-intensity aerobic exercise with at least two sessions of 8–12 repetitions of resistance exercise. Both endurance and resistance exercise help to reduce body weight, body mass index, waist circumference (WC), blood glucose and insulin levels, and blood pressure, while improving blood lipid variables [26,27]. Combining endurance and resistance exercise, or endurance-strength training and modified resistance exercise, has been reported to enhance these benefits [28,29]. We therefore expect appropriate resistance exercise to help prevent aging-related sarcopenia and MS. Studies comparing the effects of endurance exercise and endurance-resistance exercise on body composition and MS-related variables have reported conflicting results, such as that they have almost the same effects [30,31], that endurance-resistance exercise has greater effects on body composition [28,29], and that endurance-resistance exercise has almost no effects on glucose and fat metabolism [32]. In comparing the effects on the antioxidant function of HDL by static versus aerobic exercise—considering that muscle function exercise can help prevent metabolic diseases—static exercise had little effect, while aerobic exercise effectively improved antioxidant function; it has been reported that this can help reduce blood pressure [18]. However, it has been widely reported that resistance exercise can improve CVD risk factors and inflammatory markers [33], and MS-related risk factors such as diabetes [34,35]. Based on the finding that aerobic and resistance exercise had almost the same effects in diabetic patients, Yang et al. [36] concluded that resistance exercise may achieve this.

Longitudinal associative studies between exercise and HDL dysfunction have reported mixed results [37,38]. Although HDL-C structure and function are known to be associated with MS, and endurance-resistance exercise may help to maximize the anti-inflammatory effects of exercise by altering vascular endothelial function, few prior studies have addressed the effects of the form of exercise in MS. The aim of this study is to confirm the possibility that dynamic-resistance exercise for training with elastic bands in elderly women with MS can bring about positive changes in blood ApoA-I levels, inflammatory markers, and MS risk indicators. We therefore analyzed the structure of dysfunctional HDL-C based on changes in ApoA-I level following dynamic-resistance exercise in elderly women with MS. Dynamic-resistance exercise training qualitatively altered HDL, mostly by altering ApoA-I levels, relieving vascular inflammation, and improving antioxidant function, physical fitness, and MS risk factors. This supports the development of an effective exercise program to prevent and treat MS, and to reduce its prevalence.

2. Materials and Methods

2.1. Study Participant Criteria

We enrolled 40 elderly women aged ≥ 65 years; all received a detailed explanation about the objectives and procedures of the study and signed informed consent forms. The subjects were randomly selected elderly women who participated voluntarily through a recruitment notice to members of a local senior welfare center, and it is difficult to consider them as perfect general elderly women. Using the NCEP ATP III (National Cholesterol Education Program-Third Adult Treatment Panel) criteria for MS (Table 1) [39,40], subjects who satisfied at least three of the five criteria were diagnosed with MS (MS group, $n = 19$ (after one dropped out due to a musculoskeletal problem), mean age: 71.42 ± 5.87 years).

The control group comprised subjects without MS ($n = 20$, mean age: 68.23 ± 2.56 years). The study protocol, including subject selection and exercise intervention methods, was approved by the Institutional Review Board of Keimyung University (Daegu, Korea) (40525-202101-BR-087-03: 31 January 2021).

Table 1. Five diagnostic criteria for metabolic syndrome (MS) [39].

Waist Circumference	Women: ≥ 85 cm [40]
Triglyceride	≥ 150 mg/dL or under medication
HDL-C	Women: < 50 mg/dL or under medication
Blood pressure	$\geq 130/85$ mmHg or under medication
Fasting blood glucose	≥ 100 mg/dL or under medication

HDL-C: high-density lipoprotein cholesterol.

2.2. Exercise Program

The exercise program was comprised of dynamic-resistance exercise using elastic bands, three times weekly, for six months. A red band was used for acclimation to the resistance load. The dynamic-resistance exercise included large-muscle exercises of the upper and lower extremities: seated rows, elbow flexion, archery pulls for the posterior shoulder, hip flexion, hip extension, and long-sitting ankle plantar flexion, as whole-body activities. Initially, the subjects performed 2–3 sets of 10–15 repetitions, with one minute of rest between sets, for a total of 20 min [41]. The warm-up and cool-down exercises (10 min each) were comprised of mostly dynamic stretching. Exercise volume was increased every two months by adjusting the number of repetitions, sets, and the rest time: 11–13 for the first two months, 12–14 for the third and fourth months, and 13–15 for the fifth and sixth months, based on the Borg's rating of perceived exertion [42]. On-site monitoring was performed to check for hemodynamic response during exercise, and heart rate was measured after each exercise session.

2.3. Body Composition and Blood Pressure

Height was measured using a stadiometer (BSM-330, InBody, Seoul, Korea). Body weight was measured using InBody 3.0 (Biospace, Seoul, Korea). The waist–hip ratio was calculated based on waist circumference, measured at the mid-point between the top of the hip bones and the lowest palpable rib. Hip circumference was measured at the widest part of the hip. Blood pressure was measured twice in a two-minute interval using a mercury sphygmomanometer (HICO, Tokyo, Japan).

2.4. Lower Skeletal Muscle Function

Health-related fitness was measured using the senior fitness test proposed by Rikli and Jones [43]. In the tandem gait test of walking ability, subjects walked heel-to-toe, without gaps between the steps, along a 3 m straight line, and the time required was recorded. In the figure-of-eight walking test, the time required to move from the starting point to the finish point on a 3 m figure-of-eight line was recorded. To test lower extremity muscle endurance, a 30 s chair stand test was conducted. To test agility, a timed up and go (TUG) test was conducted: this measures the time required to stand up from the chair, walk 3 m, turn around, and return to the chair. To test cardiopulmonary endurance, we used the physical efficiency index (PEI), calculated as $[\text{exercise time (in seconds)} \times 100 / \text{sum of heart rate} \times 2]$, after checking heart rate three times after the Harvard step test. To test balance, one-leg standing (left and right legs), with eyes open, was performed, and the time standing with the leg raised up to the knee, while balancing with both arms raised, was measured.

2.5. Blood Collection and Biochemical Analysis

After at least 12 h of fasting, 5 mL of venous blood was collected from the antecubital vein and centrifuged. Total cholesterol, triglyceride, and LDL-C levels were analyzed on a

Hitachi 7150 auto-analyzer (Hitachi, Ltd., Tokyo, Japan). HDL-C was precipitated using a precipitating agent; the HDL-C level in the supernatant was then measured using an enzymatic method [44]. Blood glucose level was measured using the enzymatic hexokinase (HK) method, using a glucose measurement kit (GLU-HK; Asan Pharm., Seoul, South Korea): 3 μ L of the sample was reacted with 320 μ L of GLU-HKR-1 and 80 μ L of GLU-HK R-2, and absorbance was measured at a main wavelength of 340 nm and sub-wavelength of 415 nm. Insulin level was measured using an insulin ELISA kit (Mercodia, Uppsala, Sweden). Homeostatic model assessment-insulin resistance (HOMA-IR), an insulin resistance marker, was calculated as $[\text{insulin } (\mu\text{L}/\text{mL}) \times \text{glucose } (\text{mmol}/\text{L})/22.5]$, proposed by Matthews et al. [45].

2.6. ApoA-I, Pro-Inflammatory, and Anti-Inflammatory Markers

Blood C-reactive protein (CRP) (DCRP00, P183393 kit; R&D Systems, Minneapolis, MO, USA), SOD2 (KA0528 kit; Abnova, Taipei City, Taiwan), HSP70 (ADI-EKS-715, 02201818A kit; Enzo Life Sciences, Seoul, Korea), and ApoA-I (ab100635, KA0528 kit; Elabscience, Beijing, China) levels were analyzed by enzyme-linked immunosorbent assay (ELISA) [46]. TNF- α , IL-6, IL-4, and IL-5 levels were analyzed by Luminex multiplex bead-based assay (PPX-056_MXCE4A4, 191482000).

2.7. Statistical Analysis

All data were processed using SPSS 23.0 for Windows. Results are expressed as mean and standard deviation (SD). Differences between groups and time points (before and after exercise training) were analyzed using two-way repeated ANOVA for the main and interaction effects. In the case of significant interaction effects, we used a post-hoc paired *t*-test between time points by group, and a *t*-test between groups by time point. After 6 months of exercise training, Pearson correlation coefficients were calculated to analyze the relationship between changes in blood ApoA1 concentration and metabolic disease-related variables—including body composition, blood pressure, and changes in blood inflammatory markers—and antioxidant variables. Statistical significance was set to $p < 0.05$.

3. Results

3.1. Body Composition and Blood Pressure

Changes in body composition and blood pressure after 6 months of exercise training are shown in Table 2. After the exercise program, there was no significant overall change in body weight, while waist-hip ratio WHR and blood pressure tended to decrease. The MS group showed a significant decrease ($p < 0.05$) in WHR, WC, and diastolic blood pressure after exercise training, but there were no significant differences in all items before and after exercise training in the control group. Systolic blood pressure in the MS group was significantly higher ($p < 0.05$) than that of the control group, before and after exercise training, although both groups showed a tendency to decrease after exercise training.

3.2. Blood Variables

Table 3 shows the changes in metabolic disease-related blood variables after 6 months of exercise training. Namely, blood triglycerides (TG), fasting glucose, and insulin concentrations showed significant decreases in both groups. After 6 months of exercise training, the blood ApoA-1 concentration and ApoA-1/HDL-C ratio were significantly increased ($p < 0.05$) after exercise training in both groups. In the MS group, fasting glucose and insulin concentrations and HOMA-IR decreased significantly ($p < 0.05$) after exercise training, while blood ApoA-1 concentrations and ApoA-1/HDL-C ratio were significantly increased ($p < 0.05$). Before training, blood insulin concentration and HOMA-IR were significantly ($p < 0.05$) higher in the MS group than in the control group; however, after training, there was no significant difference in blood insulin concentration between these groups.

Table 2. Changes in body composition and blood pressure after exercise training.

	Control Group		MS Group		Source	F-Value	p-Value
	Pre	Post	Pre	Post			
Body weight (kg)	61.38	61.42	61.29	62.39	Time	0.019	0.891
	6.98	6.79	6.89	7.71	Group	0.283	0.601
WHR	0.89	0.88	0.92	0.89 #	T × G	0.017	0.898
	0.08	0.06	0.05	0.04	Time	7.191	0.015
WC (cm)	86.89	88.87	89.19	86.50 #	Group	0.589	0.453
	12.21	6.78	5.72	5.69	T × G	0.406	0.532
SBP (mmHg)	121.19	120.24	137.46 *	130.01	Time	18.756	0.000
	17.72	13.12	6.47	8.73	Group	0.667	0.512
DBP (mmHg)	79.21	79.32	83.72	80.18 #	T × G	0.879	0.486
	5.81	9.18	8.16	8.61	Time	1.223	0.328
				Group	10.404	0.005	
				T × G	4.215	0.098	
				Time	4.020	0.056	
				Group	0.015	0.772	
				T × G	7.305	0.022	

Values are mean and standard deviation; * $p < 0.05$, comparison between groups in a t -test between groups by time point; # $p < 0.05$, between pre and post within each group in paired t -test between time points by group; MS: metabolic syndrome; WHR: waist hip ratio; DBP and SBP: diastolic and systolic blood pressure; WC: waist circumference; T: time, G: group.

Table 3. Change of metabolic syndrome markers after exercise training.

	Control Group		MS Group		Source	F-Value	p-Value
	Pre	Post	Pre	Post			
TG (mg/dL)	123.45	112.82 #	142.81 *	135.28 *	Time	2.301	0.042
	54.34	34.68	46.67	45.62	Group	2.203	0.046
HDL-C (mg/dL)	54.25	56.42	48.37	52.81	T × G	2.432	0.037
	3.06	6.89	3.09	11.28	Time	1.206	0.252
Fasting glucose (mg/dL)	91.78	89.76	136.37 *	115.54 *#	Group	0.632	0.465
	6.67	9.56	18.09	25.61	T × G	0.012	0.954
ApoA-I (ng/mL)	4046.16	5094.83 #	1951.45 *	3395.32 *#	Time	6.212	0.045
	1470.46	1819.58	693.00	934.53	Group	10.602	0.009
ApoA-I/HDL-C ratio	75.39	92.16 #	40.73 *	68.78 #	T × G	3.458	0.068
	22.26	25.83	16.99	27.59	Time	0.410	0.538
Insulin (μU/mL)	7.38	7.20	10.39 *	8.59 #	Group	0.188	0.675
	3.61	3.20	2.90	1.68	T × G	0.191	0.673
HOMA-IR	1.50	1.55	4.54 *	2.35 *#	Time	25.155	0.000
	0.74	0.78	0.70	6.30	Group	9.236	0.007
				T × G	1.592	0.223	
				Time	3.243	0.088	
				Group	13.796	0.000	
				T × G	1.599	0.222	
				Time	2.202	0.155	
				Group	17.502	0.001	
				T × G	3.535	0.031	

Values are mean and standard deviation; * $p < 0.05$, comparison between groups in a t -test between groups by time point; # $p < 0.05$, between pre and post within each group in paired t -test between time points by group; MS: metabolic syndrome, TG: triglyceride, HDL-C: high-density lipoprotein cholesterol, HOMA-IR: Homeostatic model assessment for insulin resistance; T: time, G: group.

Changes in antioxidant factors and concentrations of inflammatory markers after 6 months of exercise training are shown in Table 4. SOD2 significantly increased ($p < 0.05$) after exercise training in both groups; similarly, IL-4 and IL-5 significantly increased

($p < 0.05$) in both groups. Blood IL-6, CRP, and TNF- α concentrations showed a tendency to decrease after exercise training in both groups, but with no significant difference. Blood HSP70 concentration showed a tendency to increase after exercise training in both groups, and in the MS group, this increase was significant ($p < 0.05$).

Table 4. Change of anti-oxidants and inflammatory markers after exercise training.

	Control Group		MS Group		Source	F-Value	<i>p</i> -Value
	Pre	Post	Pre	Post			
SOD2 (pg/mL)	50827.10	52367.78 #	50213.45	52223.88 #	Time	0.600	0.449
	11646.14	10900.60	12651.40	13070.93	Group	0.006	0.940
					T \times G	0.010	0.920
HSP70 (ng/mL)	0.55	0.69	0.55	0.85 #	Time	11.518	0.003
	0.16	0.22	0.22	0.43	Group	0.531	0.475
				T \times G	1.795	0.197	
IL-4 (pg/mL)	13.93	14.03 #	13.20	15.43 #	Time	3.726	0.045
	1.99	2.34	1.40	0.76	Group	1.323	0.345
				T \times G	1.217	0.284	
IL-5 (pg/mL)	17.07	19.86 #	16.66	19.28 #	Time	3.802	0.047
	8.94	9.52	11.42	5.50	Group	3.376	0.083
				T \times G	0.963	0.339	
IL-6 (pg/mL)	14.31	11.16	9.96	9.59	Time	2.002	0.174
	10.95	3.18	1.36	0.85	Group	1.975	0.177
				T \times G	1.237	0.281	
CRP (mg/dl)	543.72	447.50	674.91	461.82	Time	2.616	0.093
	283.59	1189.08	510.69	563.61	Group	0.090	0.767
				T \times G	1.303	0.269	
TNF- α (pg/mL)	9.20	8.36	8.14	7.84	Time	1.261	0.276
	3.03	1.34	1.47	0.89	Group	1.550	0.229
				T \times G	0.285	0.600	

Values are mean and standard deviation; # $p < 0.05$, between pre and post within each group in paired *t*-test between time points by group; SOD2: superoxide dismutase 2, HSP70: 70 kilodalton heat shock protein, CRP: C-reactive protein, IL: interleukin, TNF- α : tumor necrosis factor- α ; T: time, G: group.

3.3. Physical Fitness

The changes in physical fitness factors after 6 months of exercise training are shown in Table 5. Both groups showed improvement in all items after exercise training. In particular, after exercise training, the MS group showed a significant ($p < 0.05$) improvement in cardiorespiratory endurance, muscular endurance (30 s chair stand test), balance (TUG test), and walking ability (straight walking test), while the control group showed only significant improvement in muscle endurance (30 s chair stand test) ($p < 0.05$). However, PEI and TUG remained significantly ($p < 0.05$) lower in the MS group, compared to the control group, both before and after exercise training.

3.4. Correlation of Blood Variables with APOA-I

The exercise training-induced changes in APOA-I levels (that is, increases in both groups) were significantly positively correlated with the changes in HDL-C ($r = 0.399$, $p = 0.032$) and HSP70 levels ($r = 0.364$, $p = 0.038$), and significantly negatively correlated with changes in triglyceride ($r = -0.359$, $p = 0.028$), CRP ($r = -0.355$, $p = 0.038$), and TNF- α levels ($r = -0.366$, $p = 0.049$).

Table 5. Change of physical fitness after exercise training.

	Control Group		MS Group		Source	F-Value	<i>p</i> -Value
	Pre	Post	Pre	Post			
PEI	123.82	135.24	98.45	120.44 *	Time	5.101	0.031
	13.82	13.61	17.91	18.97	Groups	0.958	0.657
					T × G	2.008	0.302
30-s chair stand (time)	17.54	28.77 #	15.81	24.19 #	Time	81.511	0.000
	3.21	3.70	3.72	3.65	Groups	5.566	0.046
					T × G	1.658	0.370
Balance test (Left) (s)	38.02	42.63	34.01	35.17	Time	1.042	0.322
	8.77	8.10	4.30	8.05	Groups	0.546	0.471
					T × G	0.565	0.463
Balance test (Right) (s)	38.86	53.13	27.47	29.96 *	Time	2.294	0.149
	5.72	9.45	4.01	6.59	Groups	3.657	0.074
					T × G	1.132	0.303
TUG (s)	3.07	4.09	7.29 *	6.21 *	Time	0.194	0.663
	3.21	1.42	3.42	1.32	Groups	13.562	0.004
					T × G	2.453	0.246
Straight walking test (s)	7.74	7.57	8.93 #	7.71 *	Time	2.539	0.134
	2.19	1.80	1.52	2.02	Groups	2.468	0.244
					T × G	1.386	0.257
S-type walking test (s)	15.50	14.04	15.33	15.35	Time	2.659	0.142
	1.55	1.47	2.21	2.77	Groups	0.183	0.680
					T × G	2.809	0.132

Values are mean and standard deviation; * $p < 0.05$, comparison between groups in a *t*-test between groups by time point; # $p < 0.05$, between pre and post within each group in paired *t*-test between time points by group; MS: metabolic syndrome; PEI: physical efficiency index; TUG: timed up and go test; T: time, G: group.

4. Discussion

Sarcopenia and obesity, key risk factors in aging, can drastically increase the prevalence of metabolic syndrome (MS), via negative effects on arteriosclerosis and insulin resistance. Aerobic exercise is typically applied effectively in exercise programs, as a non-pharmacological approach to preventing and treating sarcopenic obesity. Our study, aiming to improve MS in the elderly, follows the growing awareness of the need to include different forms of exercise, including high-intensity interval training (HIIT) or resistance exercise, to prevent aging-related loss of lean body mass and muscle [47]. However, since lean body mass and detailed muscle analyses were not included in this study, it is difficult to determine their effect on the prevention of sarcopenia. Therefore, additional analysis is required on the effects of various high-intensity resistance training, including HIIT, which has recently been considered effective in preventing cardiovascular disease and increasing muscle mass.

We found that dynamic-resistance exercise for training with elastic bands was associated with significant reductions in the WHR and waist circumference, and significant improvements in cardiopulmonary endurance, balance, agility, and walking ability. Endurance exercise has been reported to reduce body weight and body fat. Compared to endurance exercise alone, combined resistance and endurance exercise was more effective for increasing lean body and muscle mass in diabetic patients [48], for reducing body fat and enhancing lower extremity muscle function [49], and for increasing lean body mass and reducing visceral fat [50]. For obese women, Sanal et al. [28] reported that resistance exercise was more effective than endurance exercise in reducing body fat and maintaining lower-extremity lean body mass. Here, we observed significant reductions in WHR and waist circumference and enhanced physical fitness, following dynamic-resistance exercise for training with elastic bands. Considering the increased risk of MS due to muscle mass loss during aging, our findings provide evidence that such exercise could be an effective

method for preventing sarcopenic obesity in the elderly. In need of further consideration is that after 6 months of exercise training, the control group showed a significant increase in WC, while the MS group showed a significant decrease. Such a result can be interpreted as a positive effect of dynamic-resistance exercise, but it is difficult to consider its complete effect, considering the MS group showed a significantly high WC pre-intervention, and there were a limited number of subjects to be measured. Therefore, further analysis is required.

Along with obesity, poor blood lipid values are a key risk factor for CVD [51]. Although exercise effectively improves these levels, studies on its effects have typically focused on quantitative changes in body composition and blood lipids [52]. However, the importance of qualitative analysis of HDL-C, including ApoA-I and ApoB-I, has been emphasized for analyzing its specific effects on MS [53,54]. In particular, a detailed qualitative analysis of HDL-C is considered an important diagnostic indicator for CVD and myocardial infarction [55].

TNF- α and CRP levels are elevated in patients with CVD, causing monocytes and macrophages to infiltrate arterial walls, where they accumulate [56]. In this process, native and reconstituted HDL inhibit ApoA-I mutation, as well as inhibiting the leukocyte adhesion molecule expression by endothelial cells that is activated by inflammatory stimulation [57,58]. Accordingly, HDL neutralizes inflammatory markers [59], inhibiting TNF- α expression [50]. Further, low HDL-C levels are associated with high levels of high-sensitivity CRP [60]. Therefore, qualitative changes in HDL-C affect the expression of inflammation, the primary risk factor in MS.

It has been proposed that an exercise program can effectively promote positive qualitative changes in HDL-C and inhibit inflammation. This is based on the hypothesis that increased ApoA-I-mediated HDL binding, arising from increased activation of myeloperoxidase, raises ApoA-I oxidation, and reduces chronic inflammation [61,62]. However, this mechanism has not been sufficiently demonstrated [63]. In particular, it cannot be proven that this mechanism directly reduces lipoprotein levels, which are risk factors of CVD. Following aerobic exercise, ApoA-I levels were elevated in patients with chronic obstructive pulmonary disease [64]. Moreover, in CVD, exercise training directly affected not only traditional cardiovascular risk factors, but also vascular function and structure [65]. Nonetheless, little has been reported on how exercise affects ApoA-I-mediated qualitative changes in HDL [66]. Here, in our MS group, SBP and fasting glucose were noticeably reduced, and ApoA-I and the ApoA-I/HDL-C ratio increased, following six months of active-resistance exercise training. This suggests that exercise will positively alter HDL-C, mostly via blood ApoA-I, in obese and MS patients, providing important evidence toward improving CVD risk factors [67].

Following the exercise program, we observed reductions in the levels of IL-6, CRP, and TNF- α (pro-inflammatory markers), increases in IL-4 and IL-5 (anti-inflammatory markers), and increases in SOD2 and HSP70 (important inhibitors of oxidative stress), providing evidence that vascular inflammation can be prevented through active-resistance exercise. Inflammation caused by obesity and lack of physical activity has been considered a primary cause of type II diabetes and atherosclerosis [68,69], and is associated with increases in pro-inflammatory cytokines IL-6 and TNF- α [70]. Exercise affects the phenotypic switch involved in macrophage polarization, causing a reduction in pro-inflammatory cytokines IL-6 and TNF- α and a related increase in anti-inflammatory cytokines IL-4 and IL-5, and is thus considered effective in inhibiting inflammation [71]. Moreover, the noticeable reductions in blood glucose, insulin, and HOMA-IR, basic indicators of insulin resistance, that we observed following the program, suggest that exercise may increase anti-inflammatory cytokine levels and improve insulin resistance.

Antioxidative function declines with aging. Exercise activates antioxidant factors, and in particular SOD and HSP70; this has been suggested to inhibit arteriosclerosis and insulin resistance by preventing inflammation. Exercise controls oxidative stress, protecting cardiovascular tissue by activating SOD, thereby reducing the myocardial infarct area in

the heart [72]. In particular, long-term exercise training can inhibit oxidative stress, by activating skeletal muscle adaptation and mitochondrial biogenesis; even if oxidative stress occurs, the defensive ability can be effectively enhanced by antioxidative enzymes in the mitochondria [73]. High serum HSP70 levels inhibit atherogenesis, reducing the onset of CAD [74]. In elderly rats, aerobic exercise activated SOD and HSP70 expression in muscle tissues [75]. For male rats on a high-fat diet, 12 weeks of running exercise (60 min per session, five sessions per week) was associated with higher SOD1 levels in the aorta and mesenteric artery, relative to those in the non-exercise group [76]. In a human study, it has been reported that exercise training is effective in restoring the function and structure of the heart and blood vessels with the increase in SOD1 levels [77]. Recent reports indicating that resistance training is less effective than aerobic training in activating antioxidative function [78,79] support the use of dynamic-resistance exercise, such as in our study, for restoring antioxidative function. The difference in effective changes in body composition and metabolic disease-related variables according to exercise types (endurance versus resistance) can be attributed to methodical errors, including the inappropriate composition of exercise programs. Therefore, we emphasize the necessity of continuous research for accurate analysis of the effect of the contents of different exercise programs.

Here, following dynamic-resistance exercise for training with elastic bands, our MS group showed positive changes in body composition, physical fitness, and MS-related blood variables, as well as reduced blood pressure, a basic indicator of direct vascular function. This provides evidence that active-resistance exercise to strengthen muscles can prevent MS during aging. Further, our findings show that it repairs dysfunctional HDL-C and reduces intracellular lipid accumulation by increasing vascular endothelial and cardio muscular function.

The improvements in blood ApoA-I levels following dynamic-resistance exercise may be our most important finding: changes in ApoA-I were significantly correlated with changes in body composition, blood lipid levels, and in inflammatory and antioxidative factors. ApoA-I, the most important component of HDL, ensures the function of HDL by interacting with various proteins. Reduced ApoA-I levels, or loss of its lipid-binding ability, are major causes of loss of HDL function, and the resulting dysfunctional HDL cannot form the stable HDL-C structure. CAD is associated with low serum ApoA-I levels [62], and ApoA-I is found in the HDL-C of CAD patients [80]. Among the Apo proteins, ApoA-I is the most potent antioxidant for preventing LDL oxidation and removing oxidized phospholipids from arterial wall cells and LDL [81]. CAD can thus be predicted from the inflammatory and anti-inflammatory actions of HDL [82]. However, since it showed a low overall correlation coefficient with the amount of change in ApoA-I after the exercise program, continuous analysis is needed through a design that further increases the number of subjects.

5. Conclusions

For elderly women with MS, dynamic-resistance exercise for training with elastic bands positively altered body composition, blood pressure, physical fitness, MS-related blood variables, and inflammatory markers. In particular, dynamic-resistance exercise caused qualitative changes in HDL, mostly by altering ApoA-I levels. This provides evidence that, for elderly women with MS, dynamic-resistance exercise for training with elastic bands is important in improving vascular inflammation, antioxidative function, MS risk factors, and physical fitness.

Author Contributions: Conceptualization, N.A.; methodology, N.A. and K.K.; formal analysis, N.A.; investigation, N.A.; resources, N.A.; data curation, N.A. and K.K.; writing—original draft preparation, N.A.; writing—review and editing, K.K.; visualization, N.A.; supervision, K.K.; project administration, N.A.; funding acquisition, N.A. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Ministry of Education of the Republic of Korea and the National Research Foundation of Korea (NRF-2018S1A5A2A01038357).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Keimyung University of Bonn (Daegu, Korea) (40525-202101-BR-087-03: 31 January 2021).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Sharrett, A.R.; Ballantyne, C.M.; Coady, S.A.; Heiss, G.; Sorlie, P.D.; Catellier, D.; Patsch, W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* **2001**, *104*, 1108–1113. [\[CrossRef\]](#)
- Di Angelantonio, E.; Sarwar, N.; Perry, P.; Kaptoge, S.; Ray, K.K.; Thompson, A.; Wood, A.M.; Lewington, S.; Sattar, N.; Packard, C.J.; et al. Major lipids, apolipoproteins, and risk of vascular disease. *JAMA* **2009**, *302*, 1993–2000.
- Gordon, D.J.; Probstfield, J.L.; Garrison, R.J.; Neaton, J.D.; Castelli, W.P.; Knoke, J.D.; Jacobs Jr, D.R.; Bangdiwala, S.; Tyroler, H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. *Circulation* **1989**, *79*, 8–15. [\[CrossRef\]](#)
- van Capelleveen, J.C.; Bochem, A.E.; Motazacker, M.M.; Hovingh, G.K.; Kastelein, J.J. Genetics of HDL-C: A causal link to atherosclerosis? *Curr. Atheroscler. Rep.* **2013**, *15*, 326. [\[CrossRef\]](#)
- Toth, P.P.; Barter, P.J.; Rosenson, R.S.; Boden, W.E.; Chapman, M.J.; Cuchel, M.; D’Agostino, R.B.; Davidson, M.H.; Davidson, W.S.; Heinecke, J.W.; et al. High-density lipoproteins: A consensus statement from the National Lipid Association. *J. Clin. Lipidol.* **2013**, *7*, 484–525. [\[CrossRef\]](#)
- Riwanto, M.; Landmesser, U. High density lipoproteins and endothelial functions: Mechanistic insights and alterations in cardiovascular disease. *J. Lipid Res.* **2013**, *54*, 3227–3243. [\[CrossRef\]](#) [\[PubMed\]](#)
- Weichhart, T.; Kopecky, C.; Kubicek, M.; Haidinger, M.; Doller, D.; Katholnig, K.; Suarna, C.; Eller, P.; Tolle, M.; Gerner, C.; et al. Serum amyloid A in uremic HDL promotes inflammation. *J. Am. Soc. Nephrol.* **2012**, *23*, 934–947. [\[CrossRef\]](#) [\[PubMed\]](#)
- Barter, P.J.; Nichollas, S.; Rye, K.A.; Anantharamaiah, G.M.; Navab, M.; Fogelman, A.M. Antiinflammatory properties of HDL. *Circ. Res.* **2004**, *95*, 764–772. [\[CrossRef\]](#)
- Mineo, C.; Deguchi, H.; Griffin, J.H.; Shaul, P.W. Endothelial and antithrombotic actions of HDL. *Circ. Res.* **2006**, *98*, 1352–1364. [\[CrossRef\]](#)
- Nofer, J.R.; van der Giet, M.; Tolle, M.; Wolinska, I.; von Wnuck Lipinski, K.; Baba, H.A.; Tietge, U.J.; Godecke, A.; Ishii, I.; Kleuser, B.; et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. *J. Clin. Invest.* **2004**, *113*, 569–581. [\[CrossRef\]](#) [\[PubMed\]](#)
- Tall, A.R.; Yvan-Charvet, L.; Terasaka, N.; Pagler, T.; Wang, N. HDL, ABC transporters, and cholesterol efflux: Implications for the treatment of atherosclerosis. *Cell Metab.* **2008**, *7*, 365–375. [\[CrossRef\]](#) [\[PubMed\]](#)
- Rye, K.A.; Barter, P.J. Antiinflammatory actions of HDL: A new insight. *Arterioscler. Thromb. Vasc. Biol.* **2008**, *28*, 1890–1891. [\[CrossRef\]](#)
- Khovidhunkit, W.; Kim, M.S.; Memon, R.A.; Shigenaga, J.K.; Moser, A.H.; Feingold, K.R.; Grunfeld, C. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. *J. Lipid Res.* **2004**, *45*, 1169–1196. [\[CrossRef\]](#) [\[PubMed\]](#)
- Parks, J.S.; Rudel, L.L. Alteration of high density lipoprotein subfraction distribution with induction of serum amyloid A protein (SAA) in the nonhuman primate. *J. Lipid Res.* **1985**, *26*, 82–91. [\[CrossRef\]](#)
- Gorostegi-Anduaga, I.; Corres, P.; Martinez Aguirre-Betolaza, A.; Perez-Asenjo, J.; Aispuru, G.R.; Fryer, S.M.; Maldonado-Marin, S. Effects of different aerobic exercise programmes with nutritional intervention in sedentary adults with overweight/obesity and hypertension: EXERDIET-HTA study. *Eur. J. Prev. Cardiol.* **2020**, *25*, 343–353. [\[CrossRef\]](#)
- Vanhees, L.; Geladas, N.; Hansen, D.; Kouidi, E.; Niebauer, J.; Reiner, Z.; Cornelissen, V.; Adamopoulos, S.; Prescott, E.; Borjesson, M. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular risk factors: Recommendations from the EACPR. Part II. *Eur. J. Prev. Cardiol.* **2012**, *19*, 1005–1033. [\[CrossRef\]](#)
- Georgios, A.C.; Evangelia, J.K.; Asterios, P.D.; Dimitrios, N.K. Diagnosis and treatment of dyslipidaemias in athletes. *Curr. Vasc. Pharmacol.* **2017**, *15*, 238–247.
- Pagonas, N.; Vlatsas, S.; Bauer, F.; Seibert, F.S.; Sasko, B.; Buschmann, I.; Ritter, O.; Kelesidis, T.; Westhoff, T.H. The impact of aerobic and isometric exercise on different measures of dysfunctional high-density lipoprotein in patients with hypertension. *Eur. J. Prev. Cardiol.* **2019**, *26*, 1301–1309. [\[CrossRef\]](#)

19. Casella-Filho, A.; Chagas, A.C.; Maranhao, R.C.; Trombetta, I.C.; Cesena, F.H.Y.; Silva, V.M.; Tanus-Santos, J.E.; Negrao, C.E.; da Luz, P.L. Effect of exercise training on plasma levels and functional properties of high-density lipoprotein cholesterol in the metabolic syndrome. *Am. J. Cardio.* **2011**, *107*, 1168–1172. [[CrossRef](#)]
20. Roberts, C.K.; Katiraie, M.; Croymans, D.M.; Yang, O.O.; Kelesidis, T. Untrained young men have dysfunctional HDL compared with strength-trained men irrespective of body weight status. *J. Appl. Physiol.* **2013**, *115*, 1043–1049. [[CrossRef](#)]
21. Riedel, S.; Radzanowski, S.; Bowen, T.S.; Werner, S.; Erbs, S.; Schuler, G.; Adams, V. Exercise training improves high-density lipoprotein-mediated transcription of proangiogenic microRNA in endothelial cells. *Eur. J. Prev. Cardiol.* **2015**, *22*, 899–903. [[CrossRef](#)] [[PubMed](#)]
22. Muscella, A.; Stefano, E.; Marsigliante, S. The effects of exercise training on lipid metabolism and coronary heart disease. *Am. J. Physiol. Heart Circ. Physiol.* **2020**, *319*, H76–H88. [[CrossRef](#)] [[PubMed](#)]
23. Donnelly, J.E.; Blair, S.N.; Jakicic, J.M.; Manore, M.M.; Rankin, J.W.; Smith, B.K.; American College of Sports Medicine. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. *Med. Sci. Sports Exerc.* **2009**, *41*, 459–471. [[CrossRef](#)] [[PubMed](#)]
24. Fogelholm, M.; Stallknecht, B.; van Baak, M. ECSS position statement: Exercise and obesity. *Eur. J. Sport Sci.* **2006**, *6*, 15–24. [[CrossRef](#)]
25. Jensen, M.D.; Ryan, D.H.; Apovian, C.M.; Ard, J.D.; Comuzzie, A.G.; Donato, K.A.; Hu, F.B.; Hubbert, V.S.; Makicic, J.M.; Kushner, R.F.; et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation* **2004**, *129*, S102–S138. [[CrossRef](#)]
26. Lemes, I.R.; Turi-Lynch, B.C.; Caverro-Redondo, I.; Linares, S.N.; Monteiro, H.L. Aerobic training reduces blood pressure and waist circumference and increases HDL-c in metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. *J. Am. Soc. Hypertens.* **2018**, *12*, 580–588. [[CrossRef](#)] [[PubMed](#)]
27. Oliver-Martinez, P.A.; Ramos-Campo, D.J.; Martinez-Aranda, L.M.; Martinez-Rodriguez, A.; Rubio-Arias, J.A. Chronic effects and optimal dosage of strength training on SBP and DBP: A systematic review with meta-analysis. *J. Hypertens.* **2020**, *38*, 1909–1918. [[CrossRef](#)]
28. Sanal, E.; Ardic, F.; Kirac, S. Effects of aerobic or combined aerobic resistance exercise on body composition in overweight and obese adults: Gender differences. A randomized intervention study. *Eur. J. Phys. Rehabil. Med.* **2013**, *49*, 1–11.
29. AbouAssi, H.; Slentz, C.A.; Mikus, C.R.; Tanner, C.J.; Bateman, L.A.; Willis, L.H.; Shields, A.T.; Piner, L.W.; Kraus, E.A.; Huffman, K.M.; et al. The effects of aerobic, resistance, and combination training on insulin sensitivity and secretion in overweight adults from STRRIDE AT/RT: A randomized trial. *J. Appl. Physiol.* **2015**, *118*, 1474–1482. [[CrossRef](#)]
30. Rossi, F.E.; Fortaleza, A.C.S.; Neves, L.M.; Buonani, C.; Picolo, M.R.; Diniz, T.A.; Kalva-Filho, C.A.; Papoti, M.; Lira, F.S.; Freitas, I.F., Jr. Combined training (aerobic plus strength) potentiates a reduction in body fat but demonstrates no difference on the lipid profile in postmenopausal women when compared with aerobic training with a similar training load. *J. Strength Cond. Res.* **2016**, *30*, 226–234. [[CrossRef](#)]
31. Schwingshackl, L.; Dias, S.; Strasser, B.; Hoffmann, G. Impact of different training modalities on anthropometric and metabolic characteristics in overweight/obese subjects: A systematic review and network meta-analysis. *PLoS ONE* **2013**, *8*, e82853. [[CrossRef](#)] [[PubMed](#)]
32. Jamka, M.; Mądry, E.; Krzyżanowska-Jankowska, P.; Skrypnik, D.; Szulińska, M.; Mądry, R.; Lisowska, A.; Batyrova, G.; Duś-Zuchowska, M.; Gotz-Więckowska, A.; et al. The effect of endurance and endurance-strength training on body composition and cardiometabolic markers in abdominally obese women: A randomised trial. *Sci. Rep.* **2021**, *11*, 12339. [[CrossRef](#)] [[PubMed](#)]
33. Moro, T.; Tinsley, G.; Pacelli, F.Q.; Marcolin, G.; Bianco, A.; Paoli, A. Twelve months of time-restricted eating and resistance training improves inflammatory markers and cardiometabolic risk factors. *Med. Sci. Sports Exerc.* **2021**, *53*, 2577–2585. [[CrossRef](#)] [[PubMed](#)]
34. Irvine, C.; Taylor, N.F. Progressive resistance exercise improves glycaemic control in people with type 2 diabetes mellitus: A systematic review. *Aust. J. Physiother.* **2009**, *55*, 237–246. [[CrossRef](#)]
35. Kelley, G.A.; Kelley, K.S. Impact of progressive resistance training on lipids and lipoproteins in adults: A meta-analysis of randomized controlled trials. *Prev. Med.* **2009**, *48*, 9–19. [[CrossRef](#)]
36. Yang, Z.; Scott, C.A.; Mao, C.; Tang, J.; Farmer, A.J. Resistance exercise versus aerobic exercise for type 2 diabetes: A systematic review and meta-analysis. *Sports Med.* **2014**, *44*, 487–499. [[CrossRef](#)]
37. Iborra, R.T.; Ribeiro, I.C.D.; Neves, M.Q.T.S.; Charf, A.M.; Lottenberg, S.A.; Negrao, C.E.; Nakadakare, E.R.; Passarelli, M. Aerobic exercise training improves the role of high-density lipoprotein antioxidant and reduces plasma lipid peroxidation in type 2 diabetes mellitus. *Scand. J. Med. Sci. Sports* **2008**, *18*, 742–750. [[CrossRef](#)]
38. Albaghdadi, M.S.; Wang, Z.; Gao, Y.; Mutharasan, R.K.; Wilkins, J. High-density lipoprotein subfractions and cholesterol efflux capacity are not affected by supervised exercise but are associated with baseline interleukin-6 in patients with peripheral artery disease. *Front Cardiovasc. Med.* **2017**, *4*, 9. [[CrossRef](#)]
39. National Cholesterol Education Program (US). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of high blood cholesterol in adults (Adult Treatment Panel III). *JAMA.* **2001**, *285*, 2486–2497. [[CrossRef](#)]

40. Kim, B.-Y.; Kang, S.M.; Kang, J.-H.; Kang, S.Y.; Kim, K.K.; Kim, K.-B.; Kim, B.; Kim, S.J.; Kim, Y.-H.; Kim, J.-H.; et al. 2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea. *J. Obes. Metab. Syndr.* **2021**, *30*, 81–92. [[CrossRef](#)]
41. Ahn, N.; Kim, K. The effects of resistance elastic bands exercises on salivary IgA and salivary cortisol levels in elderly women. *J. Biomed. Res.* **2018**, *29*, 889–894. [[CrossRef](#)]
42. Borg, G. *Borg's Perceived Exertion and Pain Scales*; Human Kinetics: Champaign, IL, USA, 1998.
43. Rikli, R.; Jones, C. *Senior Fitness Test Manual*; Human Kinetics: Champaign, IL, USA, 2013.
44. Friedewald, W.T.; Levy, R.I.; Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin. Chem.* **1972**, *18*, 499–502. [[CrossRef](#)] [[PubMed](#)]
45. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. *Diabetologia* **1985**, *28*, 412–429. [[CrossRef](#)] [[PubMed](#)]
46. Ookawara, T.; Haga, S.; Ha, S.; Oh-ishi, S.; Toshinai, K.; Kizaki, T.; Ji, L.L.; Suzuki, K.; Ohno, H. Effects of endurance training on three superoxide dismutase isoenzymes in human plasma. *Free Radic. Res.* **2003**, *37*, 713–719. [[CrossRef](#)]
47. Keenan, S.; Cooke, M.B.; Belski, R. The effects of intermittent fasting combined with resistance training on lean body mass: A systematic review of human studies. *Nutrients* **2020**, *12*, 2349. [[CrossRef](#)]
48. Church, T.S.; Blair, S.N.; Coreham, S.; Johannsen, N.; Johnson, W.; Kramer, K.; Mikus, C.R.; Myers, V.; Nauta, M.; Rodarte, R.Q.; et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes. *JAMA* **2010**, *304*, 2253. [[CrossRef](#)]
49. Marzolini, S.; Oh, P.I.; Brooks, D. Effect of combined aerobic and resistance training versus aerobic training alone in individuals with coronary artery disease: A meta-analysis. *Eur. J. Prev. Cardiol.* **2012**, *19*, 81–94. [[CrossRef](#)]
50. Park, S.-K.; Park, J.-H.; Kwon, Y.-C.; Kim, H.-S.; Yoon, M.-S.; Park, H.-T. The effect of combined aerobic and resistance exercise training on abdominal fat in obese middle-aged women. *J. Physiol. Anthropol. Appl. Human* **2003**, *22*, 129–135. [[CrossRef](#)]
51. Yusuf, S.; Hawken, S.; Ounpuu, S.; Dans, T.; Avezum, A.; Lanas, F.; McQueen, M.; Budaj, A.; Pais, P.; Varigos, J.; et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. *Lancet* **2004**, *364*, 937–952. [[CrossRef](#)]
52. Wood, P.D.; Stefanick, M.L.; Williams, P.T.; Haskell, W.L. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. *N. Engl. J. Med.* **1991**, *325*, 461–466. [[CrossRef](#)]
53. Arora, S.; Patra, S.K.; Saini, R. HDL-A molecule with a multi-faceted role in coronary artery disease. *Clin. Chim. Acta* **2016**, *452*, 66–81. [[CrossRef](#)] [[PubMed](#)]
54. Frank, P.G.; Marcel, Y.L. Apolipoprotein A-I: Structure-function relationships. *J. Lipid Res.* **2000**, *41*, 853–872. [[CrossRef](#)]
55. McQueen, M.J.; Hawken, S.; Wang, X.; Ounpuu, S.; Sniderman, A.; Probstfield, J.; Steyn, K.; Sanderson, J.E.; Hasani, M.; Volkova, E.; et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): A case-control study. *Lancet* **2008**, *372*, 224–233. [[CrossRef](#)]
56. Agrawal, A.; Hammond, D.J.; Singh, S.K. Atherosclerosis-related functions of C-reactive protein. *Cardiovasc. Hematol. Disord. Drug Targets* **2010**, *10*, 235–240. [[CrossRef](#)]
57. Cockerill, G.W.; Rye, K.A.; Gamble, J.R.; Vadas, M.A.; Barter, P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. *Arterioscler. Thromb. Vasc. Biol.* **1995**, *15*, 1987–1994. [[CrossRef](#)]
58. Calabresi, L.; Franceschini, G.; Sirtori, C.R.; De Palma, A.; Saresella, M.; Ferrante, P.; Taramelli, D. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. *Biochem. Biophys. Res. Commun.* **1997**, *238*, 61–65. [[CrossRef](#)]
59. Wadham, C.; Albanese, N.; Roberts, J.; Wang, L.; Bagley, C.J.; Gamble, J.R.; Rye, K.A.; Garter, P.J.; Vadas, M.A.; Xia, P. Highdensity lipoproteins neutralize C-reactive protein proinflammatory activity. *Circulation* **2004**, *109*, 2116–2122. [[CrossRef](#)]
60. Soro-Paavonen, A.; Westerbacka, J.; Ehnholm, C.; Taskinen, M.R. Metabolic syndrome aggravates the increased endothelial activation and lowgrade inflammation in subjects with familial low HDL. *Ann. Med.* **2006**, *38*, 229–238. [[CrossRef](#)]
61. Busnelli, M.; Manzini, S.; Chiara, M.; Colombo, A.; Fontana, F.; Oleari, R.; Poti, F.; Horner, D.; Bellosta, S.; Chiesa, G. Aortic gene expression profiles show how ApoA-I levels modulate inflammation, lysosomal activity, and sphingolipid metabolism in murine atherosclerosis. *Arterioscler Thromb. Vasc. Biol.* **2021**, *41*, 651–667. [[CrossRef](#)]
62. Schaefer, E.J.; Santos, R.D.; Asztalos, B.F. Marked HDL deficiency and premature coronary heart disease. *Curr. Opin. Lipidol.* **2010**, *21*, 289–297. [[CrossRef](#)]
63. Zheng, L.; Nukuna, B.; Brennan, M.L.; Sun, M.; Goormastic, M.; Settle, M.; Schmitt, D.; Fu, X.; Thoson, L.; Fox, P.L.; et al. Apolipoprotein A-I is a selective target for myeloperoxidase catalyzed oxidation and functional impairment in subjects with cardiovascular disease. *J. Clin. Investig.* **2004**, *114*, 529–541. [[CrossRef](#)] [[PubMed](#)]
64. Yazdani, R.; Marefati, H.; Shahesmaeili, A.; Nakhaei, S.; Bagheri, A.; Dastoorpoo, M. Effect of aerobic exercises on serum levels of apolipoprotein A1 and apolipoprotein B, and their ratio in patients with chronic obstructive pulmonary disease. *Tanaffos* **2018**, *17*, 82–89. [[PubMed](#)]
65. Green, D.J.; Hopman, M.T.; Padilla, J.; Laughlin, M.H.; Thijssen, D.H. Vascular adaptation to exercise in humans: Role of hemodynamic stimuli. *Physiol. Rev.* **2017**, *97*, 495–528. [[CrossRef](#)] [[PubMed](#)]

66. Green, D.J.; Eijsvogels, T.; Bouts, Y.M.; Maiorana, A.J.; Naylor, L.H.; Scholten, R.R.; Spaanderman, M.E.A.; Pugh, C.J.A.; Schreuder, T.; Jones, H.; et al. Exercise training and artery function in humans: Nonresponse and its relationship to cardiovascular risk factors. *J. Appl. Physiol.* **2014**, *117*, 345–352. [[CrossRef](#)] [[PubMed](#)]
67. Rosenkilde, M.; Rygaard, L.; Nordby, P.; Nielsen, L.B.; Stallknecht, B. Exercise and weight loss effects on cardiovascular risk factors in overweight men. *J. Appl. Physiol.* **2018**, *125*, 901–908. [[CrossRef](#)]
68. Flier, J.S. Obesity wars: Molecular progress confronts an expanding epidemic. *Cell* **2004**, *116*, 337–350. [[CrossRef](#)]
69. Mokdad, A.H.; Bowman, B.A.; Ford, E.S.; Vinicor, F.; Marks, J.S.; Koplan, J.P. The continuing epidemics of obesity and diabetes in the United States. *JAMA* **2001**, *286*, 1195–1200. [[CrossRef](#)]
70. Park, H.S.; Park, J.Y.; Yu, R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. *Diabetes Res. Clin. Pract.* **2005**, *69*, 29–35. [[CrossRef](#)]
71. Kawanishi, N.; Yano, H.; Yokogawa, Y.; Suzuki, K. Exercise training inhibits inflammation in adipose tissue via both suppression of macrophage infiltration and acceleration of phenotypic switching from M1 to M2 macrophages in high-fat-diet-induced obese mice. *Exerc. Immunol. Rev.* **2010**, *16*, 105–118.
72. Beck, D.T.; Martin, J.S.; Casey, D.P.; Braith, R.W. Exercise training reduces peripheral arterial stiffness and myocardial oxygen demand in young prehypertensive subjects. *Am. J. Hypertens.* **2013**, *26*, 1093–1102. [[CrossRef](#)]
73. Rinaldi, B.; Corbi, G.; Boccuti, S.; Filippelli, W.; Rengo, G.; Leosco, D.; Rossi, F.; Filippelli, A.; Ferrera, N. Exercise training affects age-induced changes in SOD and heat shock protein expression in rat heart. *Exp. Gerontol.* **2006**, *41*, 764–770. [[CrossRef](#)] [[PubMed](#)]
74. Starnes, J.W.; Taylor, R.P.; Park, Y. Exercise improves postischemic function in aging hearts. *Am. J. Physiol. Heart Circ. Physiol.* **2003**, *285*, H347–H351. [[CrossRef](#)] [[PubMed](#)]
75. Brown, D.A.; Jew, K.N.; Sparagna, G.C.; Musch, T.I.; Moore, R.L. Exercise training preserves coronary flow and reduces infarct size after ischemia-reperfusion in rat heart. *J. Appl. Physiol.* **2003**, *95*, 2510–2518. [[CrossRef](#)] [[PubMed](#)]
76. de Moraes, C.; Davel, A.P.C.; Rossoni, L.V.; Antunes, E.; Zanesco, A. Exercise training improves relaxation response and SOD-1 expression in aortic and mesenteric rings from high caloric diet-fed rats. *BMC Physiol.* **2008**, *8*, 12. [[CrossRef](#)]
77. Schmitt, E.E.; McNair, B.D.; Polson, S.M.; Cook, R.F.; Bruns, D.R. Mechanisms of exercise-induced cardiac remodeling differ between young and aged hearts. *Exerc. Sport Sci. Rev.* **2022**, *50*, 137–144. [[CrossRef](#)]
78. de Castro, D.L.S.; da Cunha Nascimento, D.; Orsano, V.S.M.; de Sousa Neto, I.D.; Beal, F.L.R.; Stone, W.; Dos Santos Rosa, T.; Prestes, J. Effect of high-velocity and traditional resistance exercise on serum antioxidants and inflammation biomarkers in older women: A randomized crossover trial. *Exp. Gerontol.* **2020**, *139*, 111026. [[CrossRef](#)]
79. Silva, P.R.; Nascimento, D.D.C.; de Sousa Neto, I.V.; Funghetto, S.S.; Tibana, R.A.; Navalta, J.W.; Beal, F.L.R.; Prestes, J. Effects of resistance training on muscle quality index, muscle strength, functional capacity, and serum immunoglobulin levels between obese and non-obese older women. *Int. J. Exerc. Sci.* **2021**, *14*, 707–726.
80. Van Linthout, S.; Spillmann, F.; Riad, A.; Trimpert, C.; Lievens, J.; Meloni, M.; Escher, F.; Filenberg, E.; Demir, O.; Li, J.; et al. Human apolipoprotein A-I gene transfer reduces the development of experimental diabetic cardiomyopathy. *Circulation* **2008**, *117*, 1563–1573. [[CrossRef](#)]
81. Navab, M.; Hama, S.Y.; Anantharamaiah, G.M.; Hassan, K.; Hough, G.P.; Watson, A.D.; Reddy, S.T.; Sevanian, A.; Fonarow, G.C.; Fogelman, A.M. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3. *J. Lipid Res.* **2000**, *41*, 1495–1508. [[CrossRef](#)]
82. Ansell, B.J.; Navab, M.; Hama, S.N.; Kamranpour, N.; Fonarow, G.; Hough, G.; Rahmani, S.; Mottahedeh, R.; Dave, R.; Reddy, S.T.; et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. *Circulation* **2003**, *108*, 2751–2756. [[CrossRef](#)]